Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath announced multiple presentations at ESMO Congress 2026 (Oct 23-27, Madrid), including a trial-in-progress poster for the DELUMA Phase 2 study of melphalan/HDS in liver-dominant metastatic breast cancer and a Del-Liver Phase 2 update in metastatic colorectal cancer. An independent investigator-led retrospective (N=12) of CHEMOSAT percutaneous hepatic perfusion in liver-dominant metastatic uveal melanoma reported an ORR of 66.7%, disease control of 75%, median hepatic PFS of 18.4 months, and median overall survival of 28 months, with no treatment-related deaths.
Key figures
- Drug Name
- CHEMOSAT (melphalan/HDS percutaneous hepatic perfusion)
- Phase Of Trial
- Phase 2
- Dcr
- 75%
- Orr
- 66.7%
- Cohort size
- 12
- Median cs php cycles
- 3
- Median hepatic pfs months
- 18.4
- Median overall survival months
- 28
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.